The University of California, Los Angeles School of Medicine—known as the David Geffen School of Medicine at UCLA —is an accredited medical school located in Los Angeles, California, United States. The school was renamed in 2001 in honor of media mogul David Geffen who donated $200 million in unrestricted funds.

During the past decade, UCLA conducted 79 clinical trials. In the 10-year time frame, 79 clinical trials started and 27 clinical trials were completed, i.e. on average, 34.2% percent of trials that started reached the finish line to date. In the past 5 years, 38 clinical trials started and 20 clinical trials were completed. i.e. 52.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA" #1 sponsor was "University of California, Los Angeles" with 12 trials, followed by "Eli Lilly and Company" with 5 trials sponsored, "Aimmune Therapeutics, Inc." with 4 trials sponsored, "Daiichi Sankyo, Inc." with 4 trials sponsored and "Gilead Sciences" with 4 trials sponsored. Other sponsors include 69 different institutions and companies that sponsored additional 58 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA" #1 collaborator was "AstraZeneca" with 5 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 4 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "University of California, Los Angeles" with 3 trials as a collaborator and "Astellas Pharma US, Inc." with 2 trials as a collaborator. Other collaborators include 41 different institutions and companies that were collaborators in the rest 46 trials.

According to Clinical.Site data, the most researched conditions in "UCLA" are "Breast Cancer" (6 trials), "Gastric Cancer" (6 trials), "Colorectal Cancer" (5 trials), "Peanut Allergy" (4 trials) and "Advanced Cancer" (3 trials). Many other conditions were trialed in "UCLA" in a lesser frequency.

Most popular intervention types in "UCLA" are "Drug" (73 trials), "Biological" (22 trials), "Other" (8 trials), "Device" (5 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Bevacizumab" (6 trials), "Cyclophosphamide" (6 trials), "Fludarabine" (5 trials) and "AR101" (4 trials). Other intervention names were less common.

The vast majority of trials in "UCLA" are 97 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "UCLA". undefined are not yet recruiting, 27 are recruiting, 16 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 40 completed trials in UCLA, 1 suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA, 35 "Phase 1" clinical trials were conducted, 39 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 8 trials that are defined as “Not Applicable".